Key Points
- Edwards VP Donald Bobo, Jr. sold 11,386 shares on December 12 at an average price of $83.76 for about $953,691, leaving him with 38,970 shares (a 22.61% reduction in his position).
- Company results and outlook: Edwards reported a quarterly EPS beat ($0.67 vs. $0.59) and revenue of $1.55B, set FY2025 EPS guidance of $2.560–2.620, and carries a consensus "Moderate Buy" rating with a $93.30 price target and a ~$48.2B market cap.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $84.03, for a total transaction of $85,626.57. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,848,828.06. This trade represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Edwards Lifesciences Trading Down 1.4%
Shares of NYSE EW opened at $83.06 on Friday. The firm has a 50 day moving average price of $81.62 and a two-hundred day moving average price of $79.01. The stock has a market cap of $48.20 billion, a P/E ratio of 35.80, a price-to-earnings-growth ratio of 3.79 and a beta of 0.97. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences's revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.
Institutional Trading of Edwards Lifesciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter worth approximately $25,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences in the 1st quarter worth $26,000. SouthState Corp acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $27,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $28,000. Finally, True Wealth Design LLC raised its holdings in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock worth $28,000 after buying an additional 259 shares during the last quarter. 79.46% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
EW has been the subject of a number of analyst reports. Raymond James Financial upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and set a $96.00 price objective for the company in a research report on Monday, November 3rd. Piper Sandler restated an "overweight" rating and issued a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Oppenheimer cut shares of Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a research report on Wednesday, October 8th. Wells Fargo & Company restated an "overweight" rating and issued a $96.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a report on Friday, December 5th. Finally, Royal Bank Of Canada increased their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $93.30.
Check Out Our Latest Report on EW
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
